Reader TTS

Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away.

After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile,

here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch … SANOFI AND REGENERON PHARMACEUTICALS FILED A LAWSUIT SEEKING TO PREEMPT A

POSSIBLE PATENT CHALLENGE FROM AMGEN OVER THEIR FORTHCOMING DUPIXENT DRUG FOR ATOPIC DERMATITIS. The companies want a court order declaring the drug, which the Food and Drug Administration

is expected to be approve shortly, does not infringe on an Amgen patent for a failed asthma treatment. The suit comes two months after another court blocked Sanofi and Regeneron from selling

their Praluent cholesterol drug after losing a patent infringement case to Amgen. But Praulent remains on the market during an appeal. A NOVARTIS HEART FAILURE DRUG CALLED SERELAXIN FAILED

IN A LATE-STAGE TRIAL, CASTING MAJOR DOUBTS OVER A TREATMENT ONCE SEEN AS A POTENTIAL BLOCKBUSTER, Pharmaphorum informs us. At one point, analysts expected serelaxin sales could exceed $2

billion, but this appears increasingly unlikely, since the medicine had already been rejected three years ago by regulators in the US and EU. Leerink analyst Seamus Fernandez said the trial

was a “long shot.” STAT+ Exclusive Story Already have an account? Log in THIS ARTICLE IS EXCLUSIVE TO STAT+ SUBSCRIBERS UNLOCK THIS ARTICLE — PLUS IN-DEPTH ANALYSIS, NEWSLETTERS, PREMIUM

EVENTS, AND NEWS ALERTS. Already have an account? Log in Individual plans Group plans View All Plans To read the rest of this story subscribe to STAT+. Subscribe